Comments
Suven Life Sciences today received one product patent each from the US and South Korea for CNS molecule which could be used for treating various central nervous system disorders.
The product patents are valid through 2030, Suven Life Sciences said in a filing to the BSE.
“The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD),” it added.
Commenting on the development, Suven CEO Venkat Jasti said: “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for MDD with high unmet medical need with huge market potential globally.”
With these new patents, Suven has 19 granted patents from US and 15 granted patents from South Korea, the company said.
Products out of these inventions may be out-licensed at various phases of clinical development like Phase-I or Phase-II, it added.
Shares of Suven Life Sciences were trading 4.13 per cent up at Rs 190.15 per scrip during afternoon trade on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.